Hepatitis B virus, hepatitis C virus and HIV coinfection among people living with HIV/AIDS in Buenos Aires, Argentina

The HIV epidemic in Argentina has changed since the first case was reported in 1982. Since the beginning of the 1990s, a decrease in the number parenterally acquired infections has been observed, with a marked increase in transmission through unprotected sexual contact (heterosexual and homosexual), and in the number of women living with HIV/AIDS.Fil: Laufer, Natalia Lorna. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Microbiologia. Area Virologia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Quarleri, Jorge Fabian. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Microbiologia. Area Virologia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Bouzas, María B.. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas F. J. Muñiz; ArgentinaFil: Juncos, Gerardo. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas F. J. Muñiz; ArgentinaFil: Cabrini, Mercedes. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Moretti, Franco. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Microbiologia. Area Virologia; ArgentinaFil: Bolcic, Federico Martin. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Microbiologia. Area Virologia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Fernández Giuliano, Silvina. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas F. J. Muñiz; ArgentinaFil: Mammana, Lilia. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas F. J. Muñiz; ArgentinaFil: Salomon, Horacio Eduardo. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Microbiologia. Area Virologia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Cahn, Pedro. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "juan A. Fernández"; Argentin

Baraitser-Winter cerebrofrontofacial syndrome: Delineation of the spectrum in 42 cases

Baraitser-Winter, Fryns-Aftimos and cerebrofrontofacial syndrome types 1 and 3 have recently been associated with heterozygous gain-of-function mutations in one of the two ubiquitous cytoplasmic actin-encoding genes ACTB and ACTG1 that encode β- and γ-actins. We present detailed phenotypic descriptions and neuroimaging on 36 patients analyzed by our group and six cases from the literature with a molecularly proven actinopathy (9 ACTG1 and 33 ACTB). The major clinical anomalies are striking dysmorphic facial features with hypertelorism, broad nose with large tip and prominent root, congenital non-myopathic ptosis, ridged metopic suture and arched eyebrows. Iris or retinal coloboma is present in many cases, as is sensorineural deafness. Cleft lip and palate, hallux duplex, congenital heart defects and renal tract anomalies are seen in some cases. Microcephaly may develop with time. Nearly all patients with ACTG1 mutations, and around 60% of those with ACTB mutations have some degree of pachygyria with anteroposterior severity gradient, rarely lissencephaly or neuronal heterotopia. Reduction of shoulder girdle muscle bulk and progressive joint stiffness is common. Early muscular involvement, occasionally with congenital arthrogryposis, may be present. Progressive, severe dystonia was seen in one family. Intellectual disability and epilepsy are variable in severity and largely correlate with CNS anomalies. One patient developed acute lymphocytic leukemia, and another a cutaneous lymphoma, indicating that actinopathies may be cancer-predisposing disorders. Considering the multifaceted role of actins in cell physiology, we hypothesize that some clinical manifestations may be partially mutation specific. Baraitser-Winter cerebrofrontofacial syndrome is our suggested designation for this clinical entity

Aprendizaje cooperativo. Un recurso indispensable en la formación universitaria

El Libro “Aprendizaje cooperativo Un recurso indispensable en la formación universitaria”, se enmarca dentro del Proyecto de Innovación docente Finestra Oberta UV_ SFPIE GER 15-314671, bajo la dirección de la Profesora María Elena Cobas Cobiella, del Departamento de Derecho Civil, de la Facultad de Derecho de la Universidad de Valencia. Este libro contiene 19 artículos inéditos de un grupo importante de profesores y especialistas en la temática nacionales e internacionales, así como con la intervención como colaboradores de estudiantes de Grado en Derecho, de la doble titulación Derecho- ADE de la Universidad de Valencia, y de Universidades internacionales. También han intervenido en el mismo estudiantes del Master de Mediación y Arbitraje y solución de conflictos en Derecho Privado 2015/2016 y del Proyecto Unisocietat L’Eliana Curso 2015 – 2016. Constituye una obra que eleva la práctica del aula a la teoría. Altamente recomendable para aquellos que incursionen en el camino de la docencia.The Book "Cooperative learning: an indispensable resource in university education" is part of the Project for teaching innovation "Finestra Oberta,UV_ SFPIE GER 15-314671", under the direction of Professor Maria Elena Cobas Cobiella, from Civil Law department of the Faculty of Law of the University of Valencia. This book contains 19 new articles of a large group of professors and specialists in national and international topics, as well as with the intervention as collaborators of Law degree students from the double degree Law-Business Administration from the University of Valencia, and also from international universities. They have also intervened in the book some students from the Master of Mediation, Arbitration and resolution of conflicts in Private Law 2015/2016 and from the Unisocietat L'Eliana project 2015/2016. It is a work that elevates the classroom practice towards the theory. Highly recommended for those who want to progress in the way of teaching.Los siguientes estudiantes han colaborado en la Parte Especial del Libro, con los resúmenes de sus trabajos de mapas conceptuales y los prezi:Ylenia Martínez, María Gómez Escrivá,Julieta Campora Espí, Blanca Giner Zarranz, Mario Zúñiga Martínez, Alicia Martínez Ruiz, Sandra Gimeno Bascuñana, Héctor Martínez Soler, Amparo García Navarro,Joan De la Haba Herrera,Alberto José Fourrat Calatayud, Juan Ortega Talamantes, Vicente Vila Subiela, Cristina Blázquez Sánchez, Sara Monsalve Alemany, Paula Navarro Román, Carlos Reyes Hernández,Jesús Sanz Carnero,José Guillermo Gil, Aroa Gimeno, José Manuel Aznar, Teresa Pérez, Antonio Fernández, Cristina Martin, Rodrigo Climent, José Ángel Molina Sánchez, Daniel Cabanes Ferrando, David Escobar Haro, Diego Martínez Amor, Mari Carmen Arnau Gil, Raquel Jiménez Gago, Daniel March Quevedo, Laura Alapont Vidal, Gema Canós Ferrandis, Mónica Costa Isabel, Jesús Sanmartín Viturro, Eduardo José Tobio García, Pau Viñuelas LLoria, María del Mar Figueroa Hernández, Minerva Llagunes Picazo, Lucía Olmos, José Olmedo, Brynn De Houwer, Enrique Pla Marcos, Héctor Tabernero Más, Laura Payá González, Blanca Martínez Pons,Alejandro Grima Margarit, Belén Català, Mariam Pérez, David Sánchez, Jorge Seguí ,Sara Tamarit,Fernando Aparisi Escriba, Analía Carballo Quispe,José Luis Moreno Miguel,Candy Priscilla Rojas Campoverde, Ademar Lledó Monfort, Irene Belles Rubio, Clara Calomarde Esteban, Marta Marín de la Dueña, Sergio Pinel Castillo,Maria Simo Martin, Daniel Rocher Camps, Sandra Nicolás Mascarell, Teresa Bartret García, Maria Amparo Monasort Pérez,Joan Vicente Torres Moreno, Belén Cuñat Salavert, Carmen Rodríguez Bertos, Aníbal Sánchez Gómez, Sofía Morant Muñoz, Pedro Ballester Martínez,Akbar Khawar, David Ortíz Soler, Jonathan Pérez Gutiérrez.Jorge Amat Andrés, M.ª Antonia García Juncos, Jenny Maritza González Vergara,Juan José Tocón Torres,Pau Zurita Varela, Manuel Calvo Pereiro, Carolina Luis Tamarit,Beatriz Muñoz Moncholí,Marta Conejero Sarrió, Guillermo Juarez Ginestar, Carolina Más Trullás,Ramón Fernández Pares, Carlos Hervás García,Carolina Tamarit García, Jose Belloch Ortí,Danilo Terán Taborga,Manuel Castillo Martínez, Isabel Martínez Salas, Carlos Javier Castello Domenech, Silvia Juste Frechina, Cristina Barrado Franco, Noemi De Miguel Domingo, Elena Masegosa Laurí, Maryana Seniv, Paula Sanz Perez, Liney Paola Peiró Soriano, José Manuel Zahonero Ferrer,Paula Pons Guillem,Andrea Oviedo Millán,Arnaud Wustefeld, Alba Ruiz-Santa Quiteria Lara,Lydia García Céspedes,Antonio Gomar López,Eva Piqueras García, Claudia Salvador Pérez, Joel David Alvarez Remy, Sheila Jorge Muñoz,Virginia Mendoza Leal,David Benavides Arenas, Mario Perera Sánchez, Vladimir Sarmiento Paizán,Javier Mustelier Armiñán,Diamela Salina Ocaña, Edel Morales Salazar,Fortunato Dong Oñaña,María del Carmen Carvajal Balagué,María del Carmen Daries Coll, Catalina Olmo Brazales,Mª Teresa Sánchez, Julia Serra Figuerola,Mª Nieves Valdearcos Quintín,Carmen Moraga Martín,María José Moragues, Salvador Lluch,Maribel Moreno,José Luis Coello,José Cebriá,Matilde Argente,Consuelo Martínez,Rosi Hernández,Susi García,Graciela Garibotti,Susana Bianchi,Judith Steffan,Susan Humphreys,Jesús Castellano,Ana Preus,Mª José Figueroa,Mª Teresa Carbonell,Lola Lombrera,Luisa Martínez Gordillo,Roberto Soler,Pilar Bezares Martínez, Ramón González Ferrer,Raquel González Sainz,Sacra Martínez Alarcón, Emetério Mirálles Ribot, Ramón Pubill Rocaort,Conchin Ruiz Leal, Isabel Sucarrat Bermejo,Pepa San Román Moñino,InmaTarín Arfella, Maise Tarín Arfella, Pedro Montalban,Carmen Kroebel, Lydia González, Carlos Gómez, Amparo Cuellar,Pilar Navarro,Luisa Vallejo, Encarna Monzó,Carmen Conca,Pilar Alegría, Sonia Almonacil, Inma Fernández, María José García Marcelo,Clara Olivert Pavia, Ana Herrero Martínez, Rosana Crespo Martínez, Carmen Vidal Casañ,José Ramón Villagrasa Tort,Juan Carlos López Cubero,Paco Velayos Sánchez,María de la O Pérez,Carles Montagut Alvarez, José Leopoldo Rodríguez Pla, Amanda Bernat Tinoco,Marta García Montañana, Ioana Roxana Moraru, Jenifer Perujo Plumed,María Ribera Cebolla,Amparo Esteve Cervera, Iris Pla Sempere,Juan Rafael Aranda Perozo,Jesús Collado Mas, Cristina Grimalt Molina,Isabel Rojo Lora, María Teresa Peirats Casanova,Rosana Marin Rausell, Ricardo Mejía Hidalgo,Pablo Pastor Aguilera,Daniel Trujillo Villalba,Yolanda Fuster Llidó, Lucas Lamarca Pedemonte, Gabriel Rosa Felipe

Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy

Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n = 152) and 3, 311 controls, and 67 CBD cases and 439 controls in a replication stage. Associations with meta-analysis were 17q21 at MAPT (P = 1.42 x 10(-12)),8p12 at lnc-KIF13B-1, a long non-coding RNA (rs643472;P = 3.41 x 10(-8)),and 2p22 at SOS1 (rs963731;P = 1.76 x 10(-7)). Testing for association of CBD with top progressive supranuclear palsy (PSP) GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22;rs1768208;P = 2.07 x 10(-7)) and MAPT H1c (17q21;rs242557;P = 7.91 x 10(-6)). We previously reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD susceptibility loci and show that CBD and PSP share a genetic risk factor other than MAPT at 3p22 MOBP (myelin-associated oligodendrocyte basic protein)

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Hernández Herrero, Luis Carlos, La colaboración de los Obispos auxiliares en el gobierno pastoral de las diócesis, Salamanca 2017, 211 págs. ISBN 978-84-16305-55-1

Esta publicación es la tesis doctoral defendida el pasado 28 de mayo de 2017 por Luis Carlos Hernández Herrero, clérigo de la diócesis de Ávila y alumno de la Facultad de Derecho Canónico de la Universidad Pontificia de Salamanca. En sus inicios, esta obra fue dirigida por José María Díaz Moreno SJ y luego, por Federico Rafael Aznar Gil. En este marco, el trabajo realizado se encuentra diagramado a través de una introducción, cuatro capítulos y las conclusiones generales. Además, cuenta con siete apéndices referidos al iter redaccional de las principales fuentes utilizadas a lo largo de la investigación..

La prelatura territorial: ¿una cuasidiócesis?

Resumen: Las Iglesias particulares presentan una lista que incluye la prelatura territorial, como una porción del Pueblo de Dios cuyas características eclesiales determinan que la autoridad suprema no las erija como diócesis. El presente de este instituto no recuerda que su historia posee diversas motivaciones para que así se haya establecido como Iglesia particular, no siempre siguiendo el mismo criterio para ello y quedando abierta la posibilidad futura de ser una diócesis o de modificación su condición.Abstract: Particular churches give a list that include territorial prelature as a piece of God’s people whose ecclesiastic characteristics determine that supreme authority does not erect them as a diocese. This institution does not have historical record about the reasons for having been established as a particular church. The criteria have not always been the same and the possibility is open to be a diocese or other institution in the future